Comparing side effects of different doses of immunotherapy
Treatments studied
Part of Cancer clinical trials.
This study compares standard dosing schedules of pembrolizumab or nivolumab (two immunotherapy drugs) to see which one causes fewer immune-related side effects. It is for people with solid tumors who are already eligible to receive one of these drugs as part of their standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a solid tumor cancer confirmed by biopsy or lab tests
- Your doctor says you can receive pembrolizumab or nivolumab
- Your blood counts, kidney, and liver function are within acceptable levels
- You are not currently pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your body reacts to immunotherapy drugs (like PD-1 or CTLA-4 blockers) when given for the first time. It aims to predict side effects and help make treatment safer.
This study looks at side effects from immune checkpoint inhibitors in people with solid tumors. It aims to understand why side effects happen and who might be at risk, so doctors can better manage them.
This early trial compares how often two immune system medicines—nivolumab and pembrolizumab—are given for advanced or metastatic cancers. It aims to see which dosing interval is workable and safe for people needing treatment.
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
This study looks at how side effects happen in people receiving immune checkpoint inhibitor immunotherapy for solid cancers. It uses multiple types of tests to better understand these toxicities and may help improve safety and care in the future.
This study looks at how people’s bodies respond to cancer immunotherapy and why some people get side effects. Your information and lab results may help improve how immunotherapy is managed in the future.
Hear when a new Solid Tumor Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.